BioArctic

BioArctic EBIT Margin

The EBIT Margin (Operating Margin) of BioArctic (BIOA B.ST) as of Sep 25, 2026 is 68.44 %. In the previous year, EBIT Margin (Operating Margin) was -88.79 % — a change of -177.07% (higher).

EBIT Margin

68.44 %

YoY

-177.07%

Last updated:

EBIT Margin (Operating Margin) of BioArctic is 2026 68.44 % . EBIT Margin (Operating Margin) of BioArctic was 2025 -88.79 % . It decreases by -177.07% higher compared to the previous year.

BioArctic's operating (EBIT) margin stands at 68.4%, up from -602.8% several years earlier.

The BioArctic EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
68.05 SEK
Jan 1, 2019
40.27 SEK
Jan 1, 2020
-137.28 SEK
Jan 1, 2021
-602.82 SEK
Jan 1, 2022
-4.45 SEK
Jan 1, 2023
41.01 SEK
Jan 1, 2024
-88.79 SEK
Jan 1, 2025
68.44 SEK
The BioArctic EBIT Margin history
YEAREBIT MarginYoY
68.44 %-177.07%
-88.79 %-316.50%
41.01 %-1,021.64%
-4.45 %-99.26%
-602.82 %+339.10%
-137.28 %-440.89%
40.27 %-40.82%
68.05 %+381.71%
14.13 %-80.01%
70.66 %+506.47%
11.65 %—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

EBIT Margin (Operating Margin) of BioArctic is 68.44 % in 2026.

EBIT Margin (Operating Margin) of BioArctic changed from -88.79 % to 68.44 %, representing a -177.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — BioArctic

All Key Metrics — BioArctic